S�zary syndrome with hyposplenism
✍ Scribed by Pichler, Werner J. ;Peter, Hans H. ;Anagnou, Johannes ;Kaup, Franz-Josef ;Drommer, Wolfgang
- Publisher
- Springer-Verlag
- Year
- 1984
- Weight
- 1017 KB
- Volume
- 49
- Category
- Article
- ISSN
- 1432-0584
No coin nor oath required. For personal study only.
✦ Synopsis
Phenotypic, functional and clinical analysis of two patients with Sezary Syndrome are presented. Both patients had an elevated lymphocyte count with the helper/inducer cell phenotype by analysis with monoclonal antibodies (OKT3 ÷, T4 ÷, T6-, T8-, M1-), had the characteristic cerebriform nucleus of Sezary cells, and were Fc-IgG receptor negative. The functional tests revealed no proliferative, cytotoxic or immunoregulatory activity of patient E.P.'s leukemic cells, while the lymphocytes of patient A.N. responded to mitogen stimulation and had helper cell capacity in pokeweed mitogen driven B cell differentiation and maturation. Both patients presented skin involvement, pruritus, hepatomegaly and patient E.P. showed generalized lymphadenopathy. The spleen size of patient A.N. was below the normal range with an estimated spleen weight of ~ 160 g (normal 180-229 g). Patient E.P. had an extremely small spleen size with an estimated weight of N 20 g as shown by abdominal sonography and spleen scintigraphy and had Howell-Jolly bodies within the erythrocytes. The size of the spleen in various other diseases with T cell proliferations is discussed with respect to the possible proliferative centers of the various T-cell subpopulations.
Chronic lymphocytic leukemia (CLL) of the T-cell type are rare diseases which, on the basis of functional and phenotypic analysis can be separated into proliferations of the inducer/helper or suppressor/cytotoxic T-ceU type [17]. The leukemic cells of the Sezary syndrome have the helper/inducer cell phenotype as shown by analysis with Supported by Deutsche Forschungsgemeinschaft SFB 54, G12
📜 SIMILAR VOLUMES
A case of Sezary syndrome is presented. Coincident with topical treatment by nitrogen mustard, an enormous rise in circulating Sezary cells was seen in the peripheral blood. The possibility of this rise as a result of the topical treatment is discussed as a possible danger in topical therapy for ind
We report a case of a 71-year-old male with Sézary syndrome diagnosed in 1996 who subsequently developed systemic Hodgkin's lymphoma. His only past treatment was bath psoralen plus ultraviolet A. He has since been treated with multiagent chemotherapy (ChlVPP/PABLOE) which induced a remission in his
## Abstract Sézary syndrome (SS) is a rare form of erythrodermic cutaneous T‐cell lymphoma with hematological involvement and a poor prognosis. At present little is known about the molecular pathogenesis of this malignancy. To address this issue, we analyzed 28 SS cases through the use of molecular